Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pNGVL4aCRTE6E7L2 HPV DNA Vaccine in HPV16+ High-Grade CIN
NCT04131413Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of PVX-4 in cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicities at 1 week. Started Sep 2020; status: recruiting.
02
Drugs
PVX-4
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT04131413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131413.